The dataset ranks 91 companies and individual filers by record count, with a clear leader holding 27 records, well ahead of fifth place at 11 and tenth place at 6. The top five assignees combined account for 38.0% of all 200 records in scope, so a small group holds a disproportionate share of the claim space. Beyond the leading names, the ranking spreads into a long tail of firms with only one or two filings each, which is typical for a field still drawing in specialty formulators and academic spinouts alongside the established players.

Filing peaked in 2018 at 10 records and has since eased, with the 2021-to-2024 window showing a 50% decline from 6 to 3 annual filings. That said, publication typically lags actual filing by around 18 months, so the 2025 and 2026 counts in this dataset are still incomplete and understate real activity. Read the recent-year numbers as provisional rather than as proof the technology area is winding down.

Fermentation and enzymatic synthesis methods (IPC class C12P) appear in 73.0% of the 200 records, and microorganism and genetic-engineering claims (C12N) appear in 68.0%, making these the two most densely claimed areas. Bioreactor and apparatus claims (C12M) cover a smaller 40.5% share, and adjacent domains such as sugars and nucleic acids, biocides, coatings and medicinal preparations each sit in the 10-14% range. Because a single record can carry multiple IPC classes, these shares add up to more than 100% and should not be read as parts of a whole.

The clearest gap sits in bioreactor and sensor-feedback apparatus: C12M claims cover only 40.5% of records against 73.0% for the underlying fermentation synthesis methods in C12P, meaning the control hardware that implements a feeding strategy is less densely claimed than the biological method itself. Specific sub-areas worth checking include real-time substrate-pulse sensor loops, catabolite-repression override logic, and multi-strain carbon-limitation feeding profiles. A narrow, apparatus-specific claim in one of these areas is more likely to clear prior art than a broad synthesis-method claim.

US20090181433A1, filed by Genencor International, claims methods for producing end-products through bioconversion of biomass-based feedstock substrates such as starch and cellulose, notably without requiring gelatinization or liquefaction of the substrate. It is representative of the substrate-feed and bioconversion claim style that recurs across this corpus rather than a singular outlier. Anyone designing a feedstock-conversion process that skips a gelatinization or liquefaction step should read its claims closely before assuming the approach is clear of prior art.

The United States leads with 54 filings, followed by the European Patent Office at 32 and WIPO PCT applications at 24, with Australia, Canada and India each holding smaller counts. This spread means a clearance search confined to a single office, particularly the US alone, would miss more than half of the documented filing activity. Teams planning multi-jurisdiction filings should treat the EPO and PCT routes as carrying comparable weight to a US filing in this specific field.